
News|Articles|August 1, 2004
Glycemic control and pulmonary function sustained throughout long-term use of inhalable insulin
Two studies evaluating the efficacy and long-term safety of the inhalable, rapid-acting dry powder insulin formulation (Exubera, Pfizer/Aventis) demonstrate that the drug was able to sustain glycemic control and pulmonary function in patients with type 2 diabetes
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
How new psoriasis, alopecia and atopic dermatitis therapies stood out at Fall Clinical Derm 2025
2
The FDA proposes ditching comparative efficacy studies for biosimilars
3
UC Davis develops new drug for bladder cancer patients
4
Misdiagnosis of Type 1 diabetes remains a major problem, despite advances
5

















































